FTC Says Noerr Doesn't Shield AndroGel Pay-For-Delay Deal
By Aaron Vehling ( May 8, 2014, 2:58 PM EDT) -- The Federal Trade Commission on Tuesday told a Georgia federal court that two generic drug companies did not satisfy the high burden necessary to appeal a ruling that Noerr-Pennington antitrust immunity didn't shield their alleged pay-for-delay deal over testosterone replacement treatment AndroGel....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.